VivoSeq
Gastroenterology

Liver Cirrhosis

1

Pipeline Programs↗

7

Active Trials↗

4

Companies Involved↗

Liver Cirrhosis is an early-stage landscape with 1 program across 4 companies. The most active players are Boehringer Ingelheim, Eli Lilly, Helio Genomics.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2H

Helio Genomics

0 programs

PreclinicalV

Vanessa Stadlbauer-Koellner, MD

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Foscenvivint

Kiminori Kimura, MD

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

8

clinical trials

Recruiting3 · 38%
Not yet recruiting3 · 38%
Active, not recruiting1 · 13%
Completed1 · 13%

Clinical Trials

Trial Activity

8 trials

Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma
Recruiting·HHelio Genomics·N/A·NCT05199259·1,200 enrolled
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting·HHelio Genomics·N/A·NCT05181826·1,200 enrolled
A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT07325526·29 enrolled
Prospective Clinical Trial to Detect Liver Cancer Through Quantification of cfDNA Methylation in Blood Samples: A LAM Insight Trial Study
Active, not recruiting·HHelio Genomics·N/A·NCT03694600·1,900 enrolled
A Phase 2, Multicenter, Open-label Study to Evaluate Safety and Efficacy of 500 mg BID NTZ on Top of Standard of Care in Patients With Inflammatory Phenotype Presenting Either With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure (CONTROL-ACLF)
Not yet recruiting·GGenfit·Phase 2·NCT07694297·16 enrolled
A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia
Not yet recruiting·KKiminori Kimura, MD·Phase 2·NCT07681089·4 enrolled
The Predictive Value of the Vascular Occlusion Test During Orthotopic Liver Transplantation for the Development of Early Allograft Dysfunction
Not yet recruiting·Ippokrateio General Hospital of Thessaloniki·N/A·NCT07658794·50 enrolled
Pilot Study to Evaluate the Feasibility of Collecting Duodenal Fluid With SIMBA Capsules
Completed·VVanessa Stadlbauer-Koellner, MD·Preclinical·NCT06708832·11 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)